Literature DB >> 11885664

Pharmacological influence on inner ear endothelial cells in relation to the pathogenesis of sensorineural hearing loss.

B Gloddek1, K Lamm, W Arnold.   

Abstract

Despite an increasing incidence of acute sensorineural hearing loss, the pathogenesis of this disease remains uncertain. While viral infection of the stria vascularis, organ of Corti or spiral ganglion cells is discussed in the American literature, a vascular genesis with resulting impaired perfusion of the inner ear is favoured by European investigators. Although both hypotheses are supported by different therapeutic strategies to regain normal hearing, the influence of spontaneous remission remains unclear. This study aims at combining these seemingly opposing concepts with the assumption of an immunologically mediated vasculitis with consequent cochlear hypoperfusion. We already know from other organs that during viral vasculitis circulating immunoglobulins are deposited perivascularly, which leads to a local decrease in perfusion and tissue hypoxia. Also in autoimmune diseases, perivasculitis is common with the endothelium playing a major role at the initial stages of the disease. These endothelial cells promote vasculitis by secreting pro-inflammatory cytokines like IL-1, IL-6 or TNF-alpha in addition to the expression of adhesion molecules. Due to the persistence of these immunopathological mechanisms stenosis or atresia with ischaemic necrosis results. To examine whether this pathomechanism is also important in inner ear dysfunction, the immunological response after stimulation of the cochlear endothelium of guinea pigs was determined. In addition, the influence of corticosteroids on this immune cascade was examined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11885664     DOI: 10.1159/000059254

Source DB:  PubMed          Journal:  Adv Otorhinolaryngol        ISSN: 0065-3071


  8 in total

1.  Idiopathic sudden hearing loss: another kind of circulatory risk should not be neglected.

Authors:  Antonio Pirodda; Gian Gaetano Ferri; Claudio Borghi
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-25       Impact factor: 2.503

Review 2.  Ion homeostasis in the ear: mechanisms, maladies, and management.

Authors:  Dennis R Trune
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2010-10       Impact factor: 2.064

3.  Transtympanic steroids in refractory sudden hearing loss. Personal experience.

Authors:  I Dallan; L Bruschini; A Nacci; B Fattorp; A C Traino; F Rognini; G Ferraro; P Bruschini
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-02       Impact factor: 2.124

4.  Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss.

Authors:  Nezamoddin Berjis; Saeed Soheilipour; Alireza Musavi; Seyed Mostafa Hashemi
Journal:  Adv Biomed Res       Date:  2016-06-20

5.  Idiopathic sudden sensorineural hearing loss: Effectiveness of salvage treatment with low-dose intratympanic dexamethasone.

Authors:  Pedro Salvador; Francisco Moreira da Silva; Rui Fonseca
Journal:  J Otol       Date:  2020-07-02

6.  Intratympanic steroid treatment for idiopathic sudden sensorineural hearing loss after failure of intravenous therapy.

Authors:  Emanuele Ferri; Antonio Frisina; Anna Chiara Fasson; Enrico Armato; Giacomo Spinato; Maurizio Amadori
Journal:  ISRN Otolaryngol       Date:  2012-02-19

7.  Successful treatment of sudden sensorineural hearing loss by means of pharmacotherapy combined with early hyperbaric oxygen therapy: Case report.

Authors:  Dorota Olex-Zarychta
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Interleukin-1 alpha gene polymorphism (IL-1α) and susceptibility to tinnitus in the elderly.

Authors:  Luciana Lozza de Moraes Marchiori; Marcelo Yugi Doi; Glória de Moraes Marchiori; Glenda Ventura de Souza; Regina Célia Poli-Frederico; Daiane Soares de Almeida Ciquinato
Journal:  Noise Health       Date:  2019 Mar-Apr       Impact factor: 0.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.